The outlook of companies tied to Sildenafil's legacy presents a complex investment scenario . While the initial success generated substantial gains, generic copies have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a discerning assessment of patent safeguards, evolving healthcare trends , and the pro